MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2025-09-30, MRSN had -$20,581K decrease in cash & cash equivalents over the period. -$3,192K in free cash flow.

Cash Flow Overview

Change in Cash
-$20,581K
Free Cash flow
-$3,192K

Unit: Thousand (K) dollars (except for numbers of shares and EPS)
Cash Flow
2025-09-30
2025-06-30
Net loss
-7,545 -48,419
Depreciation
83 603
Impairment loss on property and equipment
-25 -563
Net amortization of premiums and discounts on marketable securities
0 140
Stock-based compensation
1,154 4,764
Non-cash operating lease expense
859 1,683
Loss on extinguishment of debt
-378 -
Other non-cash items
3 -154
Accounts receivable
-98 266
Prepaid expenses and other current assets
525 142
Other assets
0 0
Accounts payable
-530 -1,407
Accrued expenses
-370 -3,781
Operating lease liabilities
-976 -1,878
Other liabilities
0 -594
Deferred revenue
4,160 -3,068
Net cash used in operating activities
-3,192 -51,928
Maturities of marketable securities
0 27,000
Purchase of marketable securities
0 0
Proceeds from sale of property and equipment
372 395
Purchase of property and equipment
0 0
Net cash provided by (used in) investing activities
372 27,395
Net proceeds from at-the-market facilities
0 0
Proceeds from exercise of stock options
0 0
Proceeds from sales of common stock under espp
0 29
Repayment of debt
17,729 6,250
Payments under finance lease obligations
32 24
Net cash (used in) provided by financing activities
-17,761 -6,245
Decrease in cash, cash equivalents and restricted cash
-20,581 -30,778
Cash and cash equivalents at beginning of period
108,228 -
Cash and cash equivalents at end of period
56,869 -
Unit: Thousand (K) dollars

Time Plot

Show the time plot by selecting a row from the table.

Mersana Therapeutics, Inc. (MRSN)

Mersana Therapeutics, Inc. (MRSN)